




A: B16F0 with HDR CCN4 KO




B: B16F10 with HDR CCN4 KO



C: B16F10 with DN CCN4 KO



D: YUMM1.7 with DN CCN4 KO



Supplementary Figure S9. Independent of cell line and CRISPR approach, *Ccn4* knockout consistently reduced the tumor initiation size and increased the growth rate constant, especially in immunocompromised mice. Comparison of the posterior distributions in the tumor initiation size (To , rows 1 and 2) and growth rate constant (kp , rows 3 and 4) for NSG and C57BL/6cr1 mice receiving B16F0 wt and HDR *Ccn4* KO cells (panel A), B16F10 wt and HDR *Ccn4* KO cells (panel B), B16F10 wt and DN *Ccn4* KO cells (panel C), and YUMM1.7 wt and DN *Ccn4* KO cells (panel D). The difference in growth rate constants for the same cell line variant injected into NSG versus C57BL/6 are shown in row 5, where a positive value indicates that the specific cell line grows faster in NSG than C57BL/6 mice.